ArticleInfectious diseases and therapy2023
Clinical Characteristics, Course, and Long-Term Outcomes in Patients with Talaromyces marneffei Infection: A 10-Year Retrospective Cohort Study.
Article in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Anti-interferon-γ autoantibodies syndrome and opportunistic infections: systematic literature review.Frontiers in immunology · 2025Pooled it
- Prognosis of Patients Infected WithJournal of general and family medicine · 2026Article
- Multiple recurrences of Talaromyces marneffei infection with HLH in an HIV-negative patient: a case report.BMC infectious diseases · 2026Article
- Two new clinical diagnostic models for Talaromycosis marneffei in AIDS patients within 48 h: evaluation of performance and comparison with previous models.BMC infectious diseases · 2026Article
- SevereInfection and drug resistance · 2026Article
- PANoptosis-mediated mechanisms underlying AST elevation in Talaromyces marneffei infection.PLoS neglected tropical diseases · 2025Article
- Multicenter Case-Control Study of Behavioral, Environmental, and Geographic Risk Factors for Talaromycosis, Vietnam.Emerging infectious diseases · 2025Article
- Optimization and clinical evaluation of a 5.8S rRNA quantitative PCR assay for the diagnosis of talaromycosis.Medical mycology · 2025Article
- Talaromyces Marneffei infections in five human immunodeficiency virus-negative patients with the history of predation on wild bamboo rats (Rhizomys spp) - a case series.BMC infectious diseases · 2025Article
- Serum IgE in the clinical features and disease outcomes of anti-interferon-γ autoantibodies syndrome.BMC immunology · 2025Article
- Clinical manifestations in patients with anti-IFN-γ autoantibodies syndrome and Talaromyces marneffei infection: a prospective cohort study.BMC infectious diseases · 2025Article
- Article
- Metagenomic Next-Generation Sequencing Unravels Talaromyces Marneffei-Induced Bone Destruction in an HIV-Negative Woman: A Case Report with Fatal Outcome.Infection and drug resistance · 2025Article
- HIV Complicated with Talaromyces Marneffei Multisystem Infection: A Case Report and Literature Review.Infection and drug resistance · 2025Article
- Cutaneous Talaromyces marneffei Infection in an Immunocompetent Adolescent: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Clinical immunological characteristics of anti-interferon-γ autoantibodies syndrome: a 3 year prospective cohort study.Emerging microbes & infections · 2024Article
- Article
- HIV-Negative Case ofInfection and drug resistance · 2024Article
- Identification ofInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
introductionTalaromyces marneffei (T. marneffei), a dimorphic fungus, causes local or disseminated infection in humans. We aimed to analyze the clinical characteristics, prognostic factors, and survival outcomes of patients with T. marneffei infection and compare the differences between human immunodeficiency virus (HIV)-positive and HIV-negative subgroups.
methodsWe retrospectively analyzed 241 patients with T. marneffei infection at the First Affiliated Hospital of Guangxi Medical University between January 2012 and January 2022. The overall population was stratified into HIV-positive (n = 98) and HIV-negative (n = 143) groups according to HIV status. Kaplan-Meier analysis and multivariate Cox regression models were used to determine the prognostic factors for overall survival (OS) and progression-free survival (PFS).
resultsWith a median follow-up time of 58.9 months, 120 patients (49.8%) experienced disease progression and 85 patients (70.8%) died. The 5-year rates of OS and PFS were 61.4% (95% CI 55.0-68.6%) and 47.8% (95% CI 41.5-55.1%), respectively. As an independent factor, patients who were HIV positive had better PFS (HR 0.50, 95% CI 0.31-0.82; p < 0.01) than patients who were HIV negative. Compared with patients who were HIV positive, patients who were HIV negative were older and had more probabilities of underlying diseases, chest involvement, bone destruction, and higher count of neutrophils (all p < 0.05). Hemoglobin (PFS: HR 0.62; 95% CI 0.39-1.00; p < 0.05; OS: HR 0.45; 95% CI 0.22-0.89; p = 0.02) and lymphocyte count (PFS: HR 0.06; 95% CI 0.01-0.26; p < 0.01; OS: HR 0.08; 95% CI 0.01-0.40; p < 0.01) were independent prognostic factors for PFS and OS in patients who were HIV negative.
conclusionsPatients with T. marneffei infection have a poor prognosis. Patients who are HIV positive and HIV negative have relatively independent clinical characteristics. Multiple organ involvement and disease progression are more common in patients who are HIV negative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.